• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • CMDE Analyzes the Typical Issues for Combination Product Registrations

CMDE Analyzes the Typical Issues for Combination Product Registrations

Tuesday, 24 November 2020 / Published in Medical Device, News, NMPA Registration in China

CMDE Analyzes the Typical Issues for Combination Product Registrations

On November 6, the CMDE (Center for Medical Device Evaluation) of the NMPA (National Medical Products Administration) published information about the common issues and technical difficulties for applicants registering drug-device combination products in China.

This news is important because it shows the high growth of combination products within China.

The analysis covered the following 5 common issues:

Insufficient information of the drug(s) involved

  • Information about the drug’s usage and dosage is important to ensure the drug’s safety and potency
  • Applicants should include any related study research data (pharmacy, pharmacology, toxicology, pharmacokinetics, and adverse reactions) when submitting the application and state the source and standard requirements of the drug  
  • If the pharmaceutical ingredient is a new active substance, the safety and potency of the drug should be evaluated first

Rationality for the choice of drug and medical device combination

The following questions address the risks and benefits that the applicant should consider:

  • Any clinically effective treatment cases of the drug in the past?
  • Any drug resistance cases in the Chinese population?
  • Any research conducted on the drug’s antibacterial properties?
  • Any preliminary in vitro and in vivo evaluation conducted regarding the antibacterial mechanism, safety and effectiveness of the product?

Chemical reaction affecting the combination product and its components

The applicant should always take into consideration that the final product characteristics can be affected chemically and physically when combining multiple entities together.

Research studies evaluating the chemical reaction between the drug and the medical device can help justify the manufacturer’s decision for selecting specific production processes (including product assembly) and quality control measures to create the expected final product. 

If the final combination product contains more than one drug, the applicant is required to submit the research studies on the chemical reaction between the drugs.

The increased risks occurred due to the drug and device interactions

Each individual drug and device component may already be registered in China, however, the drug stability can still be affected by the following factors:

  • Material ageing
  • Formula ratio
  • Changes in the polymer carrier

The dossier submission requires an evaluation of the stability of the polymer carrier, the formulation of the drug coating, and the reactions between the drug and the polymer carrier.

In addition, research studies should be updated for the dossier submission if there is a respective change in the original drug dosage amount that may alter the original sterilization and virus inactivation methods as well as storage conditions.

The intended clinical performance of the combination product

Drug dosage is the key to achieve the desired effects of a clinical treatment and also the key indicator to determine if the combination product is safe to use, hence applicants are recommended to indicate the dosage range contained in the device.

Under certain circumstances, applicants will be expected to conduct supplementary safety studies or carry out histopathological research studies to assess the corresponding toxicological risks.

Conclusion

The NMPA encourages manufacturers of combination products to set up early communication (before the application) with the related government officials, in order to make better preparations for the registration in China.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Combination Products, drug, Drug/Device

What you can read next

Medical Device Electronic Submission System (eRPS)
Supervision and administration of medical devices
Supervision and administration of medical device – sampling inspections finds 12 product failures
China drug registration electronic certificates
China drug registration electronic certificates now available

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP